It was a tough month for these popular shares. The post Why these top ASX shares sank 10%+ in April appeared first on The ...

First-year biomedical engineering student Kaitlin Bertrand, who was born with Fraser Syndrome, has been awarded the 2026 ...

MPR spoke with Dr Daniela Carvalho, an investigator in the CHORD trial, the results form which formed the basis for the approval of Otarmeni.

When hearing aids are no longer effective, Ryder Boen tries a cochlear implant. As it’s turned on, he’s overwhelmed by what ...

Hearing implant leader MED-EL USA is announcing two upcoming symposia at CI2026, the annual meeting of the American Cochlear Implant Association (ACIA) in Chicago. The meeting also celebrates the ...

The decision to place cochlear implants in both ears at the same time in young children may better shape brain development ...

The US Food and Drug Administration (FDA) has approved lunsotogene parvec-cwha (Otarmeni), the first gene therapy for genetic ...

The treatment, the first of its kind, was approved by the Food and Drug Administration on Thursday. “Our baby was born deaf, ...

Cochlear is the market leader in cochlear implants with consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed ...

Cochlear shares crashed nearly 41% on Wednesday in a record daily fall, ‌after the Australian hearing implants maker slashed its forecast for annual earnings, citing weak trading conditions and ...

Cochlear now expects annual underlying net profit of between A$290 million and A$330 million. It had previously guided underlying net profit to be at the lower end of a A$435 million-A$460 million ...

A woman with a rare condition that causes hearing- and vision-loss lit up when a cochlear implant was activated in one of her ...